ATA107397A - Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons - Google Patents

Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons

Info

Publication number
ATA107397A
ATA107397A AT107397A AT107397A ATA107397A AT A107397 A ATA107397 A AT A107397A AT 107397 A AT107397 A AT 107397A AT 107397 A AT107397 A AT 107397A AT A107397 A ATA107397 A AT A107397A
Authority
AT
Austria
Prior art keywords
cell clone
serum
protein
obtaining
free medium
Prior art date
Application number
AT107397A
Other languages
English (en)
Other versions
AT407255B (de
Inventor
Manfred Reiter
Wolfgang Mundt
Friedrich Dorner
Original Assignee
Immuno Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3506017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATA107397(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to AT0107397A priority Critical patent/AT407255B/de
Application filed by Immuno Ag filed Critical Immuno Ag
Priority to US09/100,253 priority patent/US6100061A/en
Priority to US09/324,612 priority patent/US6475725B1/en
Publication of ATA107397A publication Critical patent/ATA107397A/de
Application granted granted Critical
Publication of AT407255B publication Critical patent/AT407255B/de
Priority to US10/170,661 priority patent/US6936441B2/en
Priority to US11/123,362 priority patent/US7094574B2/en
Priority to US11/482,504 priority patent/US20070161079A1/en
Priority to US12/488,441 priority patent/US20090258391A1/en
Priority to US12/488,465 priority patent/US8080414B2/en
Priority to US12/778,776 priority patent/US8084251B2/en
Priority to US12/848,897 priority patent/US8084252B2/en
Priority to US12/986,111 priority patent/US8329465B2/en
Priority to US14/567,942 priority patent/USRE46745E1/en
Priority to US15/203,558 priority patent/USRE46860E1/en
Priority to US15/203,550 priority patent/USRE46897E1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0043—Medium free of human- or animal-derived components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/76—Undefined extracts from plants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2531/00—Microcarriers

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT0107397A 1997-06-20 1997-06-20 Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons AT407255B (de)

Priority Applications (14)

Application Number Priority Date Filing Date Title
AT0107397A AT407255B (de) 1997-06-20 1997-06-20 Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
US09/100,253 US6100061A (en) 1997-06-20 1998-06-19 Recombinant cell clone having increased stability in serum- and protein-free medium and a method of recovering the stable cell clone and the production of recombinant proteins by using a stable cell clone
US09/324,612 US6475725B1 (en) 1997-06-20 1999-06-02 Recombinant cell clones having increased stability and methods of making and using the same
US10/170,661 US6936441B2 (en) 1997-06-20 2002-06-12 Recombinant cell clones having increased stability and methods of making and using the same
US11/123,362 US7094574B2 (en) 1997-06-20 2005-05-06 Recombinant cell clones having increased stability and methods of making and using the same
US11/482,504 US20070161079A1 (en) 1997-06-20 2006-07-07 Recombinant cell clones having increased stability and methods of making and using the same
US12/488,441 US20090258391A1 (en) 1997-06-20 2009-06-19 Recombinant cell clones having increased stability and methods of making and using same
US12/488,465 US8080414B2 (en) 1997-06-20 2009-06-19 Recombinant cell clones having increased stability and methods of making and using the same
US12/778,776 US8084251B2 (en) 1997-06-20 2010-05-12 Recombinant cell clones having increased stability and methods of making and using the same
US12/848,897 US8084252B2 (en) 1997-06-20 2010-08-02 Recombinant cell clones having increased stability and methods of making and using the same
US12/986,111 US8329465B2 (en) 1997-06-20 2011-01-06 Recombinant cell clones having increased stability and methods of making and using the same
US14/567,942 USRE46745E1 (en) 1997-06-20 2014-12-11 Recombinant cell clones having increased stability and methods of making and using the same
US15/203,558 USRE46860E1 (en) 1997-06-20 2016-07-06 Recombinant cell clones having increased stability and methods of making and using the same
US15/203,550 USRE46897E1 (en) 1997-06-20 2016-07-06 Recombinant cell clones having increased stability and methods of making and using the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0107397A AT407255B (de) 1997-06-20 1997-06-20 Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons

Publications (2)

Publication Number Publication Date
ATA107397A true ATA107397A (de) 2000-06-15
AT407255B AT407255B (de) 2001-02-26

Family

ID=3506017

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0107397A AT407255B (de) 1997-06-20 1997-06-20 Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons

Country Status (2)

Country Link
US (1) US6100061A (de)
AT (1) AT407255B (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
EP2221361A3 (de) * 1996-08-30 2011-02-09 Life Technologies Corporation Methode zur Herstellung eines Polypeptids in vitro in einer Säugerzelle in einem Kulturmedium ohne Serum und ohne Proteine
US6475725B1 (en) * 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US6747003B1 (en) * 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
WO2001058935A2 (en) * 2000-02-11 2001-08-16 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
AU2001291653A1 (en) * 2000-10-02 2002-04-15 Novo-Nordisk A/S Industrial-scale serum-free production of recombinant factor vii in mammalian cells
US20040185534A1 (en) * 2000-10-02 2004-09-23 Knudsen Ida Molgaard Industrial-scale serum-free production of recombinant proteins in mammalian cells
US20040185535A1 (en) * 2003-03-21 2004-09-23 Giles Wilson Industrial-scale serum-free production of recombinant FVII in mammalian cells
US7445924B2 (en) * 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
EP1434857B1 (de) * 2001-10-02 2007-08-01 Novo Nordisk Health Care AG Verfahren zur herstelllung rekombinanter proteine in eukaryontischen zellen
US6830917B2 (en) 2001-12-10 2004-12-14 Baxter Healthcare S.A. Method of isolation and purification of trypsin from pronase protease and use thereof
US6825027B2 (en) 2001-12-10 2004-11-30 Baxter Healthcare S.A. Method of production of purified hepatitis a virus particles and vaccine preparation
US6951752B2 (en) 2001-12-10 2005-10-04 Bexter Healthcare S.A. Method for large scale production of virus antigen
DE60334983D1 (de) * 2002-04-30 2010-12-30 Bayer Healthcare Llc Faktor vii oder faktor viia polypeptidvarianten
JP3916516B2 (ja) * 2002-06-10 2007-05-16 独立行政法人科学技術振興機構 硬組織−軟組織界面再生用足場材料
DK1520008T3 (da) 2002-07-09 2012-10-15 Baxter Int Medium frit for dyreprotein til dyrkning af celler
AU2003264144C1 (en) * 2002-09-05 2009-12-17 Bavarian Nordic A/S Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
JP4472526B2 (ja) * 2002-09-30 2010-06-02 バイエル ヘルスケア エルエルシー 凝血活性が増加した第ＶＩＩ因子または第ＶＩＩａ因子変種
CU23097A1 (es) * 2002-10-23 2005-11-18 Centro Inmunologia Molecular Método para la obtención de líneas celulares en medio libre de proteína y líneas celulares obtenidas por este método
EP2085470B1 (de) * 2003-03-20 2012-05-16 Bayer HealthCare LLC FVII oder FVIIa Varianten
JP4915918B2 (ja) * 2003-06-19 2012-04-11 バイエル ヘルスケア エルエルシー 第ＶＩＩ因子または第ＶＩＩａ因子のＧｌａドメイン変種
AU2004294403A1 (en) 2003-12-01 2005-06-16 Novo Nordisk Health Care Ag Nanofiltration of factor VII solutions to remove virus
CA2551026A1 (en) * 2003-12-23 2005-07-14 Schering Corporation Methods for producing a549 cell lines stable in serum-free medium suspension culture
CA2565414A1 (en) * 2004-05-04 2005-11-24 Novo Nordisk Health Care Ag O-linked glycoforms of polypeptides and method to manufacture them
AU2005282380A1 (en) * 2004-09-07 2006-03-16 Archemix Corp. Aptamer medicinal chemistry
US7566701B2 (en) * 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
JP2008512098A (ja) 2004-09-07 2008-04-24 アーケミックス コーポレイション フォン・ビルブラント因子に対するアプタマー、および血栓性疾患の処置剤としてのその使用
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
JP5523674B2 (ja) * 2005-02-11 2014-06-18 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 植物タンパク質加水分解産物を含有する血清フリーの細胞培養液におけるポリペプチドの生産
US20070231895A1 (en) * 2005-11-02 2007-10-04 Lee Gene W Methods for adapting mammalian cells
ES2474573T3 (es) 2006-01-04 2014-07-09 Baxter International Inc Medio de cultivo celular sin oligop�ptidos
EP2423307A1 (de) * 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modifizierte Gerinnungsfaktor-IV-Polypeptide und deren Verwendung bei der Behandlung
EP2150264A4 (de) 2007-04-26 2014-09-24 Bayer Healthcare Llc Stabilisierung flüssiger lösungen eines rekombinanten proteins für gefrorene lagerung
WO2008150495A2 (en) * 2007-06-01 2008-12-11 Archemix Corp. Vwf aptamer formulations and methods for use
SI2574677T1 (sl) 2007-12-27 2017-11-30 Baxalta GmbH Procesi celične kulture
JP2011512877A (ja) * 2008-03-12 2011-04-28 ワイス・エルエルシー 組換えタンパク質の大スケール産生に適した細胞を同定する方法
PT2356247E (pt) * 2008-11-12 2015-10-26 Baxalta Inc Método de produção de fator vii isento de soro e de insulina
NZ597727A (en) 2009-07-31 2013-08-30 Baxter Int Cell culture medium for adamts protein expression
EP4218797B9 (de) 2009-09-21 2025-04-30 Takeda Pharmaceutical Company Limited Stabilisierte flüssigkeit und lyophilisierte adamts13-formulierungen
EA202090067A3 (ru) 2010-07-08 2020-07-31 Баксалта Инкорпорейтид Способ получения рекомбинантного adamts13 в культуре клеток
EP2606119A1 (de) 2010-08-20 2013-06-26 Wyeth LLC Zellkultur aus wachstumsfaktorfreien adaptierten zellen
PL2616090T3 (pl) 2010-09-17 2023-12-18 Takeda Pharmaceutical Company Limited Stabilizowanie immunoglobulin poprzez wodną formulację z histydyną o ph od słabo kwaśnego do obojętnego
TWI595004B (zh) 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
AU2012290004B2 (en) 2011-08-02 2014-11-27 Takeda Pharmaceutical Company Limited Systems and methods to increase protein yield from recombinant manufacturing processes
AU2013202965B2 (en) 2013-03-15 2016-07-21 Takeda Pharmaceutical Company Limited Improved method for producing factor h from a plasma precipitation fraction
TWI656839B (zh) 2013-03-15 2019-04-21 健臻公司 高密度細胞儲存方法
US9700486B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
JP6195191B2 (ja) * 2013-08-08 2017-09-13 極東製薬工業株式会社 無タンパク質・無脂質培地馴化細胞株を用いた組換えタンパク質の製造方法
JP6190205B2 (ja) * 2013-08-08 2017-08-30 極東製薬工業株式会社 無タンパク質・無脂質培地馴化細胞株、その製造方法及び培地
EP3957173A1 (de) 2014-09-18 2022-02-23 Genzyme Corporation Verfahren für ultrahochdichte zellbanken
EP4127158A2 (de) 2020-04-02 2023-02-08 Takeda Pharmaceutical Company Limited Adamts13-variante, zusammensetzungen und verwendungen davon

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4978616A (en) * 1985-02-28 1990-12-18 Verax Corporation Fluidized cell cultivation process
EP0531562A1 (de) * 1991-09-11 1993-03-17 Doerr, Hans-Wilhelm, Prof. Dr. med. Kultivierung von Säugetierzellen
ATE542891T1 (de) * 1994-11-10 2012-02-15 Baxter Healthcare Sa Verfahren zur herstellung von biologischen produkten in protein-freier kultur
CA2211630A1 (en) * 1995-02-23 1996-08-29 Quest International B.V. Peptides for tissue and cell culture media
AUPN442295A0 (en) * 1995-07-26 1995-08-17 Commonwealth Scientific And Industrial Research Organisation Regulated autocrine growth of mammalian cells

Also Published As

Publication number Publication date
US6100061A (en) 2000-08-08
AT407255B (de) 2001-02-26

Similar Documents

Publication Publication Date Title
HUP9900995A3 (en) Artificial stone for stabilising traffic areas in the open
HUP0000302A3 (en) Ob fusion protein compositions and methods
DK0712862T3 (da) Selektiv acylering af epsilon-aminogrupper i insulin
DK0802941T3 (da) Biologisk nedbrydelige polymerer, fremgangsmåde til fremstilling deraf, samt deres anvendelse til fremstilling af biologisk
DE69631796D1 (de) Verfahren und zusammensetzung zur reduktion der säure in kaffee
ID18494A (id) Turunan pirazola leburan dan proses pembuatannya
FI952679L (fi) Uusia seoksia, menetelmä niiden valmistamiseksi sekä niiden käyttö päällystyksiin
DE69904062D1 (de) Fischer-tropsch-dieselbrennstoff mit verbesserter stabilität und verfahren zu dessen herstellung
DK0809666T4 (da) Biologisk nedbrydelige polymerer, fremgangsmåder til deres fremstilling samt deres anvendelse til fremstilling af bionedbrydelige formlegemer
GB2315752A8 (en) Heat stable anti-freeze proteins
DE69700813D1 (de) Verwendung von stabilen aminofunktionellen latexen in wässrigen tinten
DE69901178D1 (de) Nichtgesinterte elektrode und verfahren zur herstellung
DE69812987D1 (de) Satellitenanordnung und verfahren mit mehreren luftschnittstellen standards
DE69815789D1 (de) Kniegelenkendprothese mit verbesserter hinterer Stabilität und Massnahmen zur Verhinderung einer Dislokation
DE59915087D1 (de) Verfahren zur kontrolle von schadorganismen in kulturen von bt-baumwolle
HUP0003825A2 (en) Method for preparing solution with high chloramine contentration and its use
NO992693D0 (no) Celledelt radiosystem med forbedrede egenskaper i grenseomrÕder
DE59900960D1 (de) Latentwärmekörper mit porenstruktur und verfahren zu dessen herstellung
FI970097A7 (fi) Proteiinit, jotka ovat peräisin nisäkkäiden maksasta ja niiden käyttö onkologiassa
DE69906173D1 (de) Verfahren zur Herstellung von Oxyalkylenderivaten in Gegenwart von Phosphinoxiden
IL109717A0 (en) Cell surface proteins and methods for the preparation and use thereof
AU4910299A (en) Gene and protein involved in liver regeneration
DE59805666D1 (de) Aliphatische Alkanale mit verbesserter Lagerstabilität und Verfahren zur Verbesserung der Lagerstabilität
NO20002436D0 (no) Sammensetning og fremgangsmÕte for fjerning av fosfationinnholdet i vann
SI1121382T1 (sl) Fuzijski proteini interferona-beta in uporabe

Legal Events

Date Code Title Description
MK07 Expiry

Effective date: 20170620